Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements.
based on the latest available research, will assist practitioners in the development of a rational approach to the diagnosis and treatment of hypertension in companion animals.
| BP MEASUREMENT
Diagnosing and treating hypertension in the clinical patient necessitate accurate measurement of the patient's BP. Direct BP determination entails catheterization of a suitable artery and assessing arterial pressure using an electronic transducer. [1] [2] [3] Although this is the gold standard, it is not practical for hypertension screening and treatment.
Clinically, noninvasive indirect estimations of BP such as Doppler and oscillometric devices are commonly used. [4] [5] [6] Ideally, BP should be measured using devices that have been validated in the species of interest and under the circumstances in which the patient is being tested. Standards for the validation of indirect BP measuring devices in people are well established, 7 but no device has met these criteria in conscious dogs or cats. For this reason, a set of standards for validating indirect BP devices in awake dogs and cats has been proposed and accepted. 8 Although many studies have attempted to validate indirect BP devices in anesthetized patients, only a few have been performed in conscious animals. [9] [10] [11] [12] In the devices studied to date in awake animals, either a different validation standard was used 9, 11, 12 or the device failed to meet the previously established criteria. 10 Until devices that can meet the guidelines for measuring BP in conscious animals have been validated, it is our recommendation that currently available devices be used with a degree of caution. Because estimates of BP obtained using an indirect device can only be interpreted in light of results of appropriate validation testing in conscious animals, devices that have not been subjected to appropriate testing in conscious animals should not be used. Nonetheless, studies that have relied upon indirect estimation of BP using available devices have identified adverse effects of increased BP and benefits of intervention, indicating that some of these devices can provide clinically useful information. 13, 14 Therefore, we recommend that, once commercially available, only devices that meet the established validation standards in conscious cats and dogs be used.
To obtain reliable results in the measurement of BP, it is important to follow a standard protocol ( Table 1 ). The individual taking the measurements should be skilled and experienced in the handling of animals and the equipment. Studies have shown that operator experience can have a significant impact on BP measurements. 1, 15 Often the most skilled individual is a well-trained technician and not a veterinarian. Anxiety-or excitement-induced situational hypertension can be marked, 16, 17 but can be minimized by measuring BP in a quiet area, away from other animals, before other procedures and only after the patients have been acclimated to their surroundings for 5-10 minutes.
Whenever possible, the owner should be present and restraint should be kept to a minimum. The selection of a correctly sized cuff is critical in obtaining accurate measurements. 1 Some veterinary-specific oscillometric devices have specially designed cuffs and these should always be used. When using Doppler and many oscillometric units, the width of the cuff should be 30%-40% of the circumference of the extremity at the site of cuff placement. The first measurement should be discarded and the average of 5-7 consecutive consistent indirect measurements should be obtained. If there is substantial variation, the readings should be discarded and the process repeated. In some patients, BP trends downward as the measurement process continues.
In these animals, measurements should continue until a plateau is general, use of headphones by the measurer does not result in lower BP measurements. 18 
| NORMAL VALUES FOR CANINE AND FELINE BP
Various studies have reported values for BP in normal dogs and cats (Table 2) . These values vary, reflecting differences in subject • Calibration of the BP device should be tested semiannually either by the user, when self-test modes are included in the device, or by the manufacturer.
• The procedure must be standardized.
• The environment should be isolated, quiet, and away from other animals. Generally, the owner should be present. The patient should not be sedated and should be allowed to acclimate to the measurement room for 5-10 minutes before BP measurement is attempted.
• The animal should be gently restrained in a comfortable position, ideally in ventral or lateral recumbency to limit the vertical distance from the heart base to the cuff (if more than 10 cm, a correction factor of +0.8 mm Hg/cm below or above the heart base can be applied).
• The cuff width should be approximately 30%-40% of circumference of the cuff site.
• The cuff may be placed on a limb or the tail, taking into account animal conformation and tolerance, and user preference.
• The same individual should perform all BP measurements following a standard protocol. Training of this individual is essential.
• The measurements should be taken only when the patient is calm and motionless.
• The first measurement should be discarded. A total of 5-7 consecutive consistent values should be recorded. In some patients, measured BP trends downward as the process continues. In these animals, measurements should continue until the decrease plateaus and then 5-7 consecutive consistent values should be recorded.
• Repeat as necessary, changing cuff placement as needed to obtain consistent values.
• Average all remaining values to obtain the BP measurement.
• If in doubt, repeat the measurement subsequently.
• Written records should be kept on a standardized form and include person making measurements, cuff size and site, values obtained, rationale for excluding any values, the final (mean) result, and interpretation of the results by a veterinarian.
populations, measurement techniques, and animal handling. This variability emphasizes the importance of standardization of technique in veterinary practice. Additional factors affect what is considered "normal" BP. In people, age-related increases in SBP and pulse pressure have been well characterized. 19 The effect of age is less clear in dogs and cats. A small increase in BP of 1-3 mm Hg/year has been noted with aging in dogs, 20, 21 but such an age effect has not been observed in all studies. 22, 23 In 1 study, BP increased with age in a heterogeneous population of cats, 24 but no age effect was observed in 2 other studies of normal cats. 4, 25 In an additional study of apparently healthy cats, a comparatively small increase of 1.5 mm Hg/year was noted for mean BP. 26 More recently, a larger study identified an increase in BP over time in cats aged >9 years of age with repeated BP measurements, but the risk of developing hypertension was lower in apparently healthy cats than in those with azotemic chronic kidney disease (CKD). 27 A large cross-sectional study also has identified an increase in BP with age in apparently healthy cats, 28 but the cats were not screened for concurrent disease.
An effect of sex on BP was identified in 1 study of dogs 20 in which intact males had higher BP and intact females had lower BP as compared to neutered dogs; in all cases, differences among groups were <10 mm Hg. In other studies, no association between sex and higher or lower BP was found. 29, 30 Most cats evaluated by veterinarians are neutered and in most studies an effect of sex has not been evident in this species. 24, 26 In a recent large study, males had higher BP than females and neutered cats had higher BP than intact animals, but the differences were very small. 28 There are substantial interbreed differences in canine BP, most notably for hounds (eg, Greyhounds, Deerhounds) in which BP is higher than in mongrels 31 by approximately 10-20 mm Hg. 20, 29, 31, 32 The BP among other breeds varies by 7-10 mm Hg 20,33 perhaps based on temperament. [34] [35] [36] The panel recognizes the need for breedspecific BP ranges to be developed. In cats, no effect of breed has been observed on BP. 24, 28 Obesity is associated with increases in BP in several species. [37] [38] [39] [40] [41] [42] This effect has been studied experimentally in dogs. 37, 43 A small (<5 mm Hg) increase in BP was noted in obese dogs by oscillometry 20 but not by Doppler sphygmomanometry. 22 The relationship between obesity and higher BP in dogs may be related to the prevalence of underlying disease. 30 In cats, no effect of obesity on BP was observed by oscillometry, 24 but cats that were underweight had slightly lower BP when measured with Doppler than those that were of ideal body weight or obese. 28 Recent studies suggested no association among body condition score, body weight, and SBP measurements in dogs or cats, but muscle condition score and sarcopenia have been reported to affect radial but not coccygeal BP measurements in the cat. 44, 45 Blood pressure measurement results in normal animals are highly variable based on breed, temperament, patient position, measurement method, operator experience, and intrapatient variability, 15, 17, 29, 46, 47 and it is difficult to determine a single value and range that might be applicable to all dogs or cats. Ranges of expected values in many studies of normal dogs and cats using various measurement techniques are presented in Table 2 . In disease-free patient populations, in which the BP values typically are expected to be distributed normally,
expected normal values are presented as mean AE SD, but in hypertensive patients, the frequency distribution of BP measurements tends to be skewed with fewer patients having very high measurements. 48 For this reason, the panel recommends that data from future studies of abnormal populations be presented as median and interquartile range.
| HYPERTENSION DEFINITIONS
The term systemic hypertension is applied to sustained increases in SBP, and generally can be categorized into 1 of 3 types. It may be caused by environmental or situational stressors, it may occur in association with other disease processes that increase BP (ie, secondary hypertension), or it may occur in the absence of other potentially causative disease processes (ie, idiopathic hypertension). Accordingly, we suggest the definitions and criteria described below. Unfortunately, the effects of anxiety on BP are not predictable, and some animals exhibit a marked increase in BP whereas others do not. Some animals even may exhibit a decrease in BP as a result of the measurement process. 16 In human patients, awareness of the phenomena of "white coat" hypertension and of "masked hypertension"
| Situational hypertension
(the latter term applied to cases in which in-clinic BP measurements are normal for a patient who is hypertensive in the nonmedical environment) has encouraged the evaluation of ambulatory or at-home BP as a complement to conventional in-clinic BP measurements. 52, 53 Whether masked hypertension is important in veterinary species is unclear, and the use of ambulatory BP monitoring has not been systematically evaluated in veterinary medicine.
| Secondary hypertension
Secondary hypertension represents persistent, pathologically increased BP concurrent with a disease or condition known to cause hypertension (Table 3) , or hypertension associated with the administration of a therapeutic agent or ingestion of a toxic substance known to cause an increase in BP (Table 4) . Hypertension may persist despite effective treatment of the primary condition [54] [55] [56] and BP may increase after treatment is initiated. 57 The presence of a condition known to cause secondary hypertension, even if effectively resolved by therapeutic intervention, should prompt serial follow-up evaluations.
| Idiopathic hypertension
The term "primary" or "essential" hypertension often is used in people to describe persistent pathological hypertension in the absence of any identifiable underlying cause and represents a complex multifactorial disorder involving genetic, lifestyle, and environmental factors. Essential hypertension has been reported in dogs. [58] [59] [60] [61] [62] Because subclinical kidney disease is present frequently in people and animals with hypertension, a valid diagnosis of primary or essential hypertension can be difficult to establish. Furthermore, the presence of chronically increased BP suggests that one or more of the neurohumoral and renal systems responsible for regulating BP is abnormal. Thus, the panel recommends the use of the term "idiopathic" in place of "essential" for animals in which high BP occurs in the absence of an overt clinically apparent disease that is known to cause secondary hypertension. Although secondary hypertension is most common in dogs and cats, idiopathic hypertension is more common than previously recognized, accounting for approximately 13%-20% of cases in cats. 13, 63, 64 Approximately 12% of nonazotemic nonhyperthyroid cats were hypertensive at baseline in one report, 65 and in a more recent study of 133 apparently healthy initially normotensive cats aged ≥9 years, 7% developed idiopathic hypertension over the study's follow-up period. 27 
| TARGET ORGAN DAMAGE (TOD)
Systemic hypertension is problematic only because chronically sustained increases in BP cause injury to tissues; the rationale for treatment of hypertension is prevention of this injury. Damage that results from the presence of sustained high BP is commonly referred to as end organ or TOD (Table 5 ) and the presence of TOD generally is a strong indication for antihypertensive treatment.
Hypertension has been associated with proteinuria and histological renal injury in both experimental studies and in naturally occurring disease, an effect that has been identified in several species including humans, 66, 67 dogs, 14, 68, 69 and cats. 70, 71 Proteinuria, in turn, has been associated with more rapid progression of renal disease and increased all-cause mortality in numerous clinical settings, including CKD and hypertension. 70, 72 Antihypertensive treatment generally decreases the severity of proteinuria, at least if the hypertension is severe.
13,72-74
What remains unproven, at least in dogs and cats, is whether or not this decrease in proteinuria with antihypertensive drug treatment mitigates renal injury, or is simply a surrogate for improved renal outcomes, such as rate of decrease in GFR (usually assessed by measurement of serum creatinine concentration) or renal-related mortality. 13, 72 Although the benefit is unproven, hypertension-induced or hypertension-exacerbated proteinuria currently remains an attractive target for treatment in veterinary patients.
Several epidemiological studies have associated hypertension with proteinuria (and in some studies specifically albuminuria) in cats with naturally occurring diseases. 70, 72, 74 In addition, albuminuria has been related to an increase in BP in experimental studies of induced renal disease in cats. 75 A recent study of cats found that even with anti-hypertensive treatment, higher time-averaged SBP was associated with glomerulosclerosis and hyperplastic arteriolosclerosis 
240-242
• Systemic hypertension (ie, SBP ≥160) is uncommon in dogs administered agents with pure glucocorticoid activity at clinically relevant dosages. 240, [242] [243] [244] Mineralocorticoids Dog • At high dosages and in normal dogs, administration of desoxycorticosterone (DOC) is associated with statistically significant increases in BP, 245, 246 most especially when combined with unilateral nephrectomy or high dietary sodium intake. 247, 248 • Desoxycorticosterone pivalate (DOCP), administered at clinically relevant dosage rate (2.2 mg/kg IM q 30 days) to dogs with naturally occurring hypoadrenocorticism was not associated with significant increase in BP. 249 Erythropoiesis-stimulating agents Dog, cat • Worsening or onset of systemic HT is common in animals with CKD related anemia when treated with recombinant human erythropoietin, 250 recombinant canine or feline erythropoietin, 251, 252 or darbepoetin alfa. 253, 254 • 96% of dogs administered darbepoetin alfa experienced an increase in BP 253 • 37% of previously normotensive cats developed HT during darbepoetin alfa treatment 254 • HT noted in 40% and 50% of dogs and cats, respectively, treated with rhEPO 250 • It is difficult to know to what degree disease progression alone contributes to observed BP increases.
Phenylpropanolamine (PPA) Dog • Normal dogs administered PPA (1.5-12.5 mg/kg PO), experience transient, significant increases in BP peak 30-120 minutes post-dose and last approximately 3-5 hours.
255
• Persistent HT is uncommon when administered long-term at recommended dosage (1.5 mg/kg PO q8h) in incontinent dogs.
256,257
• At high doses, acute intoxication may cause severe systemic HT. 258, 259 Phenylephrine hydrochloride Dog Systemic HT reported in normal dogs, 260 and those scheduled for cataract surgery, 261 administered topical ocular phenylephrine hydrochloride.
Ephedrine Dog Significant increases in direct BP were noted in normal dogs administered ephedrine (1.5 mg/kg PO q12h). 262 Pseudoephedrine Dog • At high doses, acute intoxication may cause systemic HT.
263
• When administered for long term to dogs with urinary incontinence, significant increases in indirect BP were not noted. 257 Toceranib phosphate Dog Systemic HT documented in 28% of previously normotensive dogs treated for various neoplastic diseases for 14 days. 264 Chronic, high-dose sodium chloride
• BP in normal cats and dogs appears to be relatively salt-insensitive.
134,265-267
• High-sodium diets do not appear to promote HT in cats with reduced renal function, 131, 266 and salt-induced HT in the dog seems to be limited to experimental models that also involve nephrectomy 268, 269 or mineralocorticoid administration. 248 • BP effects of high-sodium intake in cats and dogs with pre-existing naturally occurring systemic HT, have not been systematically evaluated.
Intoxicants with which systemic hypertension has been reported/associated: Agents associated with systemic hypertension in people, but whose BP effects have not been well characterized in dogs and cats: guarana (caffeine), ma huang (ephedrine), tacrolimus, licorice, and bitter orange. 276, 277 lesions after the patient's death. 71 However, this effect was not replicated in a second, smaller, study. 76 In dogs with azotemic CKD, magnitude of BP has been associated with proteinuria, and this has been associated with shortened survival times. 14, 77 Hypertension also was associated with shorter renal survival, but only if proteinuria was excluded from the analysis. 14 Proteinuria was directly related to the extent of increase in BP and to the rate of decrease in GFR in an experimental study in dogs. 78 Dogs with leishmaniasis frequently have proteinuria and systemic hypertension, even when nonazotemic, although in this setting the proteinuria is thought to relate mainly to immune-mediated glomerular lesions, rather than occurring as a consequence of the hypertension. 68, 79 Hypertensive greyhounds have an increased prevalence of microalbuminuria, although most dogs do not have histological evidence of renal injury. 29 Hypertension may be present in any stage of CKD, and serum creatinine concentration is not directly related to BP. 4, 80 Hypertensive cats and dogs often have minimal or no azotemia. 81 Ocular lesions are observed in many cats with hypertension and although prevalence rates for ocular injury vary, the frequency of ocular lesions has been reported to be as high as 100%. 60 106 Hypertension appears to be a risk factor for ischemic myelopathy of the cranial cervical spinal cord, resulting in ambulatory tetraparesis or tetraplegia with intact nociception in old cats. 107 Cardiac abnormalities are common in hypertensive cats 63, 64, 82 and dogs. 108 When affected, the heart is a target organ and increased cardiac output is rarely the cause of hypertension in animals. 63 The presence of diseases or conditions causally associated with secondary hypertension (Table 3) , treatment with pharmacological agents with a known effect on BP, or known or suspected exposure to intoxicants that may increase BP ( 
| DIAGNOSIS OF HYPERTENSION
The diagnosis of hypertension always should be based on reliable BP and not associated with measurement error or situational hypertension, the search for conditions associated with secondary hypertension (Table 3) should begin.
Hypertension in both dogs and cats is classified based on the risk of TOD:
• Normotensive (minimal TOD risk) SBP <140 mm Hg
• Prehypertensive (low TOD risk) SBP 140-159 mm Hg
• Hypertensive (moderate TOD risk) SBP 160-179 mm Hg
• Severely hypertensive (high TOD risk)SBP ≥180 mm Hg At this time, information regarding breed-specific reference ranges is limited, but sight hounds are known to have higher inhospital BP than other breeds. 32, 128 This difference appears to be because of situational hypertension and not a true difference in SBP. 17 Nevertheless, a risk of TOD has been proposed for these dogs when in-hospital SBP is >180 mm Hg. 129 These guidelines likely will be refined as additional breed-specific information becomes available.
In people, decreasing BP in hypertensive people lowers the risk of For most patients, the onset of hypertension has been gradual and it can be treated and controlled as outlined below, but a few patients may experience acute increases in BP resulting in hypertensive choroidopathy, encephalopathy, or rapidly progressive acute kidney injury. In these patients, the increase in BP should be considered a hypertensive emergency. For recommendations regarding the management of these patients, the reader is referred to the section on hypertensive emergencies. should be adjusted on re-evaluation if SBP is ≥160 mm Hg, with a minimal goal of treatment being to achieve a decrease in SBP to ≤160 mm Hg (Table 6 ). Blood pressure <120 mm Hg, combined with clinical findings of weakness, syncope, or tachycardia, indicates systemic hypotension and treatment should be adjusted accordingly ( Figure 2 ).
Although frequently recommended as an initial step in the pharmacological management of high BP (Figure 2 ), dietary salt restriction is controversial, 84, 130, 131 and available evidence suggests that substantial sodium restriction alone generally does not decrease BP. [130] [131] [132] Although sodium restriction activates the renin-angioten- 84 The panel therefore recommends avoiding high dietary sodium chloride intake. However, the selection of appropriate diet should include other patient-specific factors, such as underlying or concurrent diseases and palatability. If an antihypertensive regimen is ineffective, the usual decision is to increase the dosage of currently used agents or to add an alternative agent. A variety of other agents have BP-lowering efficacy (Table 7 ) and these may be used as appropriate in patients for which risk reduction is not adequate with ACEi or CCB or a combination of (Figure 2 ). Although diuretics are frequently administered to hypertensive people, these agents are not first-choice drugs for veterinary patients, particularly given the prevalence of CKD in hypertensive dogs and the adverse consequences of diuretic-induced dehydration and volume depletion in this setting. However, diuretics can be considered in the small subset of hypertensive animals in which volume expansion is clinically apparent (eg, those with edema).
| Management of hypertension in dogs
Antihypertensive agents in general, and RAAS inhibitors in particular, should be used with caution in dehydrated dogs in which GFR may decrease precipitously with their use. Unless severe hypertension with rapidly progressive TOD is present, these patients should be carefully rehydrated and then re-evaluated before instituting antihypertensive treatment.
| Management of hypertension in cats
Despite the potential role of either the systemic or intrarenal RAAS axis in the pathogenesis or maintenance of hypertension, 151 Rarely, dosages of up to 2.5 mg per cat per day however may be required. Given the efficacy of amlodipine as an antihypertensive agent, careful investigation of owner compliance should occur before increasing to the dose of amlodipine. Research evaluating plasma amlodipine concentration indicates that the need for dose escalation to adequately control BP appears to relate to severity of the hypertension rather than to body weight or amlodipine pharmacokinetics. 151 Although transdermal application has been explored, efficacy of this route of administration has not been established and PO administration is therefore the preferred route of administration. 153, 154 Adverse effects of amlodipine, including peripheral edema and gingival hyperplasia, are rarely reported in the dog and are also uncommon in cats. Although gingival hyperplasia has been reported in licensing studies during administration to young healthy cats, this seems to be relatively rare in clinical practice. 155, 156 Despite dramatic antihypertensive efficacy, longitudinal control of SBP with amlodipine besylate has not been shown to increase survival time in hypertensive cats, 64, 157 and its use may activate the systemic or intrarenal RAAS. 148 A key predictive factor in the survival of hypertensive cats is proteinuria. A significant decrease in proteinuria has been identified in cats that are initially either borderline proteinuric or proteinuric when treated with CCB. 157 However, although the combined use of amlodipine and an ACEi or amlodipine and an ARB is reportedly well tolerated, 158, 159 studies exploring any additional survival benefit of add-on antiproteinuric agents in hypertensive cats that remain proteinuric after BP control with amlodipine besylate are lacking. Nevertheless, based on the potential for proteinuria to contribute to the development and progression of renal disease in cats and its association with survival of cats with CKD, 65, 160, 161 antiproteinuric treatment should be considered in this situation. 162, 163 Telmisartan is an ARB currently licensed in Europe for the treatment of feline proteinuria due to CKD. 158 Initial studies in healthy anesthetized cats undergoing radiotelemetric BP monitoring, telmisartan, but not losartan, significantly attenuated the pressor response to angiotensin I. 164 Attenuation of the SBP rise was significantly higher than for benazepril when telmisartan was administered at a higher than currently licensed dosage (3 mg/kg PO q24h). 164 More recently, a double-blinded, randomized, placebo-controlled clinical trial has explored the use of telmisartan administered at a dosage of 2 mg/kg/ day for the treatment of naturally occurring hypertension in cats. 165 In this study, after 14 days of treatment, a significantly larger decrease in mean SBP from baseline was identified for the telmisartan-treated The combination of amlodipine besylate and telmisartan was shown to be well tolerated in a small number (n = 8) of cats in which the antiproteinuric efficacy of telmisartan was evaluated, but the antihypertensive effect of telmisartan was not a primary outcome in this study. 158 Use of ACEi in cats as a first-line antihypertensive agent is not recommended. Although statistically significant decreases in SBP have been identified when direct arterial BP monitoring is possible, the decrease in SBP is small (AE10 mm Hg) and unlikely to be sufficient in most cats. 166 However, benazepril has been used in cats that require a second antihypertensive agent and, clinically, the combination of ACEi and amlodipine besylate is well tolerated. Pheochromocytoma has been reported rarely in the cat. [179] [180] [181] [182] Combination treatment with phenoxybenzamine, an α 1 -and α 2 -adrenergic blocker, and amlodipine besylate, may be required to adequately control BP in affected cats. 181 For cats in which tachyarrhythmias are of concern, beta-adrenergic blocker (eg, atenolol) treatment may be considered, but it should only be added after α-adrenergic blockade. For cats undergoing adrenalectomy, careful BP monitoring is required in the postoperative period, as persistent hypertension or hypotension may occur. To bridge these gaps, we recommend large multicenter clinical studies aimed at refining our understanding of normal BP and how it is best assessed. In addition, long-term studies are necessary to determine the best approach to hypertension treatment, and how these treatments will affect patient quality of life and life expectancy of our patients. We hope this document will be updated periodically to reflect advances in the field of veterinary medicine.
| Hypertensive emergencies
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